Free tool
FAERS Monitor: Talzenna
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217439 or its brand name (Talzenna, Talazoparib Tosylate). Reports on generic versions are filed under their own applications.
Reports
1,853
Serious
1,494
81% of reports
Hospitalization
632
Death reported
342
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaemia285
- death194
- neoplasm progression171
- fatigue137
- off label use101
- thrombocytopenia100
- haemoglobin decreased85
- malignant neoplasm progression80
- platelet count decreased79
- febrile neutropenia71
- pancytopenia71
- nausea67
- asthenia63
- neutropenia63
- dyspnoea50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 21 |
| 2018 | 29 |
| 2019 | 210 |
| 2020 | 202 |
| 2021 | 154 |
| 2022 | 199 |
| 2023 | 252 |
| 2024 | 239 |
| 2025 | 336 |
| 2026 | 204 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 171 | 56.1 | 48.6 | 9,170 |
| anaemiaSignal | 285 | 17.0 | 15.3 | 4,304 |
| pancytopeniaSignal | 71 | 14.4 | 11.5 | 876 |
| febrile neutropeniaSignal | 71 | 12.2 | 9.7 | 718 |
| thrombocytopeniaSignal | 100 | 10.2 | 8.4 | 820 |
| haemoglobin decreasedSignal | 85 | 9.4 | 7.6 | 633 |
| malignant neoplasm progressionSignal | 80 | 8.9 | 7.2 | 553 |
| platelet count decreasedSignal | 79 | 8.4 | 6.8 | 511 |
| neutropeniaSignal | 63 | 5.3 | 4.1 | 214 |
| deathSignal | 194 | 2.6 | 2.2 | 190 |
| fatigue | 137 | 2.0 | 1.7 | 70 |
| asthenia | 63 | 1.9 | 1.5 | 27 |
| off label use | 101 | 1.3 | 1.1 | 7 |
| dyspnoea | 50 | 1.0 | 0.8 | 0 |
| nausea | 67 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.